Products
Oportuzumab Biosimilar scFv Antibody Fragment (EPCAM) for Research
Pre-Made Oportuzumab biosimilar, scFv, Anti-EPCAM Antibody: Anti-Ber-Ep4/BerEp4/DIAR5/EGP-2/EGP314/EGP40/ESA/HNPCC8/KS1/4/KSA/M4S1/MIC18/MK-1/MOC-31/TACSTD1/TROP1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
A fusion protein immunotoxin consisting of a humanized, single-chain monoclonal antibody fragment specific for the epithelial cell adhesion molecule (EpCAM) conjugated with a truncated form of Pseudomonas exotoxin A with potential antineoplastic activity.
Order Information
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-ab-408-1mg | 1mg | 3090 |
| GMP-Bios-ab-408-10mg | 10mg | |
| GMP-Bios-ab-408-100mg | 100mg | |
| GMP-Bios-ab-408-xmg | ＞100mg |
Product Details
| Products Name (INN Index) | Pre-Made Oportuzumab biosimilar, scFv, Anti-EPCAM Antibody: Anti-Ber-Ep4/BerEp4/DIAR5/EGP-2/EGP314/EGP40/ESA/HNPCC8/KS1/4/KSA/M4S1/MIC18/MK-1/MOC-31/TACSTD1/TROP1 therapeutic antibody |
| INN Name | Oportuzumab |
| Target | EPCAM |
| Format | scFv |
| Derivation | |
| Species Reactivity | Human |
| CH1 Isotype | na |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Preregistration |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2008 |
| Year Recommended | 2009 |
| Companies | University of Zurich;National Cancer Institute (USA);Sesen Bio;Viventia Biotechnologies |
| Conditions Approved | na |
| Conditions Active | Bladder cancer;Head and neck cancer |
| Conditions Discontinued | Liver cancer;Ovarian cancer |
| Development Tech | na |
About target - EPCAM
1. Protein Epithelial cell adhesion molecule
2. Gene EPCAM
3. Organism Homo sapiens (Human)
Function
May act as a physical homophilic interaction molecule between intestinal epithelial cells (IECs) and intraepithelial lymphocytes (IELs) at the mucosal epithelium for providing immunological barrier as a first line of defense against mucosal infection. Plays a role in embryonic stem cells proliferation and differentiation. Up-regulates the expression of FABP5, MYC and cyclins A and E.
